PL1663141T3 - Wodny roztwór farmaceutyczny zawierający oksymetazolinę i/lub ksylometazolinę - Google Patents

Wodny roztwór farmaceutyczny zawierający oksymetazolinę i/lub ksylometazolinę

Info

Publication number
PL1663141T3
PL1663141T3 PL04740995T PL04740995T PL1663141T3 PL 1663141 T3 PL1663141 T3 PL 1663141T3 PL 04740995 T PL04740995 T PL 04740995T PL 04740995 T PL04740995 T PL 04740995T PL 1663141 T3 PL1663141 T3 PL 1663141T3
Authority
PL
Poland
Prior art keywords
xylometazoline
solution containing
aqueous pharmaceutical
pharmaceutical solution
oxymetazoline
Prior art date
Application number
PL04740995T
Other languages
English (en)
Inventor
Frank Böhme
Bernd Eschenbach
Dagmar Färber
Claudia Hey
Barbara Pfaff
Marion Tschaikin
Original Assignee
Maria Clementine Martin Klosterfrau Vertriebsges Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34201503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1663141(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Maria Clementine Martin Klosterfrau Vertriebsges Mbh filed Critical Maria Clementine Martin Klosterfrau Vertriebsges Mbh
Publication of PL1663141T3 publication Critical patent/PL1663141T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL04740995T 2003-08-13 2004-07-14 Wodny roztwór farmaceutyczny zawierający oksymetazolinę i/lub ksylometazolinę PL1663141T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10337186A DE10337186A1 (de) 2003-08-13 2003-08-13 Wässrige Wirkstoff-Lösung
PCT/EP2004/007780 WO2005018601A1 (de) 2003-08-13 2004-07-14 Wässrige phramateuziche lösung enthaltend oxymetazolin und/oder xylometazolin
EP04740995A EP1663141B1 (de) 2003-08-13 2004-07-14 Wässrige pharmazeutische lösung enthaltend oxymetazolin und/oder xylometazolin

Publications (1)

Publication Number Publication Date
PL1663141T3 true PL1663141T3 (pl) 2007-07-31

Family

ID=34201503

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04740995T PL1663141T3 (pl) 2003-08-13 2004-07-14 Wodny roztwór farmaceutyczny zawierający oksymetazolinę i/lub ksylometazolinę

Country Status (19)

Country Link
US (1) US20060222718A1 (pl)
EP (1) EP1663141B1 (pl)
JP (1) JP4750703B2 (pl)
KR (1) KR20060065677A (pl)
CN (1) CN100531733C (pl)
AT (1) ATE357212T1 (pl)
AU (1) AU2004266443A1 (pl)
BR (1) BRPI0413478A (pl)
CA (1) CA2535533C (pl)
CY (1) CY1107633T1 (pl)
DE (2) DE10337186A1 (pl)
DK (1) DK1663141T3 (pl)
ES (1) ES2282871T3 (pl)
MX (1) MXPA06001596A (pl)
PL (1) PL1663141T3 (pl)
PT (1) PT1663141E (pl)
RU (1) RU2343918C2 (pl)
WO (1) WO2005018601A1 (pl)
ZA (1) ZA200602071B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005075735A (ja) * 2003-08-28 2005-03-24 Rohto Pharmaceut Co Ltd オキシメタゾリン含有組成物
DE102007052380A1 (de) † 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
CN101576539B (zh) * 2009-06-19 2012-05-23 广东省药品检验所 一种盐酸赛洛唑啉中杂质a的测定方法
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
DE102012005452A1 (de) 2011-12-30 2013-07-04 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die nasale Applikation mit verbesserter Stabilität
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
EP3236933B1 (en) 2014-12-24 2018-11-14 JADRAN - GALENSKI LABORATORIJ d.d. A nasal composition containing sea water as stability-improving excipient
RU2018143564A (ru) * 2016-05-17 2020-06-17 Пропонент Байотек Гмбх Карбоновая кислота, предназначенная для лечения/предупреждения заложенности носа
DE102017117987A1 (de) 2017-07-31 2019-01-31 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Zusammensetzung für die nasale Applikation
CN107362141B (zh) * 2017-08-16 2018-06-05 深圳大佛药业股份有限公司 一种盐酸羟甲唑啉鼻喷雾剂及其制备方法
US20210244710A1 (en) * 2018-07-02 2021-08-12 Kangping Xiao Stable pharmaceutical formulations of oxymetazoline
US10799481B1 (en) * 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders
WO2021194893A1 (en) 2020-03-24 2021-09-30 Cyrano Therapeutics, Inc. Treatment of chemosensory dysfunction from a coronavirus infection
ES3039833T3 (en) 2021-09-22 2025-10-24 Jadran Galenski Laboratorij D D An improved pharmaceutical composition for nasal use, preparation, and use thereof
CN117982422B (zh) * 2024-04-03 2024-07-26 深圳大佛药业股份有限公司 一种用于治疗鼻炎的喷雾剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478565A (en) * 1990-03-27 1995-12-26 Warner-Lambert Company Treatment of sinus headache
DE19549421C2 (de) * 1995-11-10 1999-11-18 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
DE69901936T2 (de) * 1998-01-30 2002-11-28 Novartis Consumer Health S.A., Nyon Nasale lösungen
JPH11302184A (ja) * 1998-04-21 1999-11-02 Taisho Pharmaceut Co Ltd 点鼻用組成物
NL1011016C2 (nl) * 1999-01-13 2000-07-14 Dagra Pharma Bv Neusspray op basis van xylometazoline en kamille-extract.
WO2000078297A2 (de) * 1999-06-22 2000-12-28 Boehringer Ingelheim International Gmbh Stabile xylometazolin- und oxymetazolinlösung
CA2423354C (en) * 2000-09-20 2009-12-15 Lee Shahinian Jr. Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
RU2212235C1 (ru) * 2001-12-24 2003-09-20 Закрытое акционерное общество "Брынцалов-А" Капли назальные бризолин, обладающие сосудосуживающим, противовоспалительным и противоотечным действием

Also Published As

Publication number Publication date
ATE357212T1 (de) 2007-04-15
RU2006107446A (ru) 2007-09-20
WO2005018601A1 (de) 2005-03-03
DE502004003305D1 (de) 2007-05-03
EP1663141B1 (de) 2007-03-21
CY1107633T1 (el) 2013-03-13
DK1663141T3 (da) 2007-07-30
US20060222718A1 (en) 2006-10-05
RU2343918C2 (ru) 2009-01-20
ES2282871T3 (es) 2007-10-16
CA2535533C (en) 2011-10-18
BRPI0413478A (pt) 2006-10-17
CN100531733C (zh) 2009-08-26
AU2004266443A1 (en) 2005-03-03
CN1832726A (zh) 2006-09-13
JP4750703B2 (ja) 2011-08-17
JP2007501817A (ja) 2007-02-01
ZA200602071B (en) 2007-05-30
KR20060065677A (ko) 2006-06-14
PT1663141E (pt) 2007-06-27
MXPA06001596A (es) 2006-05-19
CA2535533A1 (en) 2005-03-03
EP1663141A1 (de) 2006-06-07
DE10337186A1 (de) 2005-03-17

Similar Documents

Publication Publication Date Title
DK1663141T3 (da) Vandig farmaceutisk oplösning indeholdende oxymetazolin og/eller xylometazolin
MXPA05008909A (es) Formulacion intranasal de rotigotina.
NZ597757A (en) Aqueous insulin preparations containing methionine
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
CU23367A3 (es) Formulación de moxifloxacino con sal común
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
GEP20084340B (en) Pharmaceutical compositions comprising fentanyl for intranasal delivery
NO20053398D0 (no) Farmasoytiske preparater av sertaconazol for vaginal anvendelse.
AR035266A1 (es) Solucion desinfectante basada en hipoclorito sodico y procedimiento para su preparacion
GEP20125525B (en) Stable liquid pharmaceutical composition based on trazodone
IL162801A0 (en) Preparation for wound healing and prevention of bandage adhesion to the wound
TW200722097A (en) Aqueous inhalation pharmaceutical composition
NO20055882L (no) Farmasoytiske formuleringer omfattende amoksicillin og klavulanat
EP1525884A4 (en) AQUEOUS, LIQUID PREPARATIONS AND LIGHT-STABILIZED AQUEOUS LIQUID PREPARATIONS
GEP20084463B (en) Use of the distrontium salt of the acid 2-[n,n-di(carboxy methyl) amino]-3-cyano-4-carboxymethyl-thiophene-5-carboxylate for the production of medicaments for the treatment of gastro-duodenal pain
DE602005001918D1 (de) S-tenatoprazolnatrium-monohydrat-salz und dessen verwendung in form eines protonenpumpenhemmers
WO2004080188A3 (en) Methods for reducing meat discoloration
MXPA04002640A (es) Esteres de analogos de 3-desoxi-vitamina d3.
RU2004125211A (ru) Способ профилактики заболеваний птиц
HRP20070081T5 (hr) Nazalni farmaceutski pripravak piribedila
WO2005062761A3 (en) Stabilized prednisolone sodium phosphate solutions
SE0401942D0 (sv) New antimicrobial peptide complexes
RU2000105080A (ru) Препарат для лечения гриппа
SI1937245T1 (sl) Spojina uporabna za preprečevanje in zdravljenjeleve ventrikularne hipertofije pri dializiranih pacientih